Abhaya Kumar of Shasun Pharma believes Q4 is always a better quarter and hopes to maintain revenue growth and EBITDA at around current levels.
The fourth quarter earnings will begin from Friday. In an interview to CNBC-TV18, Varatharajan Sivasankaran of ICICI Securities outlined his expectations from stocks across various sectors.
Uday Baldota, Senior Vice President-Finance & Accounts, Sun Pharma said the company will continue to hold stake in Taro despite their termination of the merger agreement.
Abhaya Kumar, MD of Shasun Pharmaceuticals said the Q3 margins were stressed owing to price pressures from the US.
Abhaya Kumar, managing director of Shasun Pharmaceuticals, tells CNBC-TV18 that the jump in margins is sustainable going ahead.
In an exclusive interview with CNBC-TV18, Uday Baldota of Sun Pharma says the company saw significant growth in Sun Pharma’s standalone numbers, while as well "Taro reported strong margins this quarter." The leading drugmaker discloses that the company is "bearing additional costs for some non-revenue generating businesses."